Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β-Associated Cognitive Decline in Older Adults.

Aged Aged, 80 and over Amyloid beta-Peptides / metabolism Attention / physiology Cognition / physiology Cognitive Dysfunction / metabolism Dementia / metabolism Disease Progression Executive Function / physiology Female Humans Male Memory / physiology Neuropsychological Tests
Alzheimer’s disease Dementia Elderly/geriatrics/aging Mild cognitive impairment

Journal

Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists
ISSN: 1873-5843
Titre abrégé: Arch Clin Neuropsychol
Pays: United States
ID NLM: 9004255

Informations de publication

Date de publication:
26 Jul 2019
Historique:
received: 14 05 2018
revised: 20 08 2018
accepted: 11 09 2018
pubmed: 3 10 2018
medline: 24 4 2020
entrez: 2 10 2018
Statut: ppublish

Résumé

To prospectively examine 8-year risk of clinical disease progression to mild cognitive impairment (MCI)/dementia in older adults ≥60 with superior episodic memory (SuperAgers) compared to those cognitively normal for their age (CNFA). Additionally, to determine the extent to which SuperAgers were resilient to the negative effects of elevated amyloid-beta (Aβ+) on cognition. Participants were classified as SuperAgers based on episodic memory performance consistent with younger adults aged 30-44 and no impairment on non-memory tests (n = 179), and were matched with CNFA on age, sex, education, and follow-up time (n = 179). Subdistribution hazard models examined risk of clinical progression to MCI/dementia. Linear mixed models assessed the effect of Aβ on cognition over time. Prevalence of Aβ+ and APOE ε4 was equivalent between SuperAgers and CNFA. SuperAgers had 69%-73% reduced risk of clinical progression to MCI/dementia compared to CNFA (HR: 0.27-0.31, 95% CI: 0.11-0.73, p < .001). Aβ+ was associated with cognitive decline in verbal memory and executive function, regardless of SuperAger/CNFA classification. In the absence of Aβ+, equivalent age-related changes in cognition were observed between SuperAgers and CNFA. SuperAgers displayed resilience against clinical progression to MCI/dementia compared to CNFA despite equivalent risk for Alzheimer's disease (AD); however, SuperAgers had no greater protection from Aβ+ than CNFA. The deleterious effects of Aβ on cognition persist regardless of baseline cognitive ability. Thus, superior cognitive performance does not reflect resistance against the neuropathological processes associated with AD, and the observed resilience for SuperAgers may instead reflect neuropsychological criteria for cognitive impairment.

Identifiants

DOI: 10.1093/arclin/acy078 PMID: 30272115
pubmed: 30272115
pii: 5112955
doi: 10.1093/arclin/acy078
doi:

Substances chimiques

Amyloid beta-Peptides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

585-598

Informations de copyright

© The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Christa Dang (C)

Department of Obstetrics and Gynaecology, Melbourne Medical School, The University of Melbourne, Parkville, Victoria, Australia.
The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.

Karra D Harrington (KD)

The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.
Cooperative Research Centre for Mental Health, Parkville, Victoria, Australia.

Yen Ying Lim (YY)

The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.

David Ames (D)

Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia.
National Ageing Research Institute, Parkville, Victoria, Australia.

Jason Hassenstab (J)

Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.
Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
Department of Psychological & Brain Sciences, Washington University, St. Louis, MO, USA.

Simon M Laws (SM)

Cooperative Research Centre for Mental Health, Parkville, Victoria, Australia.
Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.
School of Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Western Australia, Australia.

Nawaf Yassi (N)

The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.
Department of Medicine and Neurology, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia.

Martha Hickey (M)

Department of Obstetrics and Gynaecology, Melbourne Medical School, The University of Melbourne, Parkville, Victoria, Australia.

Stephanie R Rainey-Smith (SR)

Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.
Australian Alzheimer's Research Foundation, Ralph and Patricia Sarich Neuroscience Research Institute, Nedlands, Western Australia, Australia.

Joanne Robertson (J)

The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.

Christopher C Rowe (CC)

Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia.
Department of Medicine, Austin Health, The University of Melbourne, Melbourne, Victoria, Australia.

Hamid R Sohrabi (HR)

Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.
Department of Biomedical Sciences, Macquarie University, Sydney, Australia.

Olivier Salvado (O)

CSIRO Health and Biosecurity, the Australian eHealth Research Centre, Brisbane, Queensland, Australia.

Michael Weinborn (M)

Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.
Australian Alzheimer's Research Foundation, Ralph and Patricia Sarich Neuroscience Research Institute, Nedlands, Western Australia, Australia.
School of Psychological Science, University of Western Australia, Crawley, Western Australia, Australia.

Victor L Villemagne (VL)

The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.
Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia.
Department of Medicine, Austin Health, The University of Melbourne, Melbourne, Victoria, Australia.

Colin L Masters (CL)

The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.

Paul Maruff (P)

The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.
CogState Ltd., Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Superior Memory Reduces 8-year Risk of Mild...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Superior Memory Reduces 8-year Risk of Mild...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Peptides bêta-amyloïdes › Superior Memory Reduces 8-year Risk of Mild...
questionsmedicales.fr › Phénomènes psychologiques › Attention › Superior Memory Reduces 8-year Risk of Mild...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Cognition › Superior Memory Reduces 8-year Risk of Mild...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Troubles de la cognition › Dysfonctionnement cognitif › Superior Memory Reduces 8-year Risk of Mild...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Superior Memory Reduces 8-year Risk of Mild...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Superior Memory Reduces 8-year Risk of Mild...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Fonction exécutive › Superior Memory Reduces 8-year Risk of Mild...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Superior Memory Reduces 8-year Risk of Mild...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Mémoire › Superior Memory Reduces 8-year Risk of Mild...
questionsmedicales.fr › Disciplines et activités comportementales › Tests psychologiques › Tests neuropsychologiques › Superior Memory Reduces 8-year Risk of Mild...